v3.26.1
Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Jul. 31, 2026
Jul. 31, 2025
Operating expenses        
General and administrative $ 1,590,917 $ 684,716 $ 5,534,840 $ 2,574,576
Research and development, net 588,958 723,048 1,876,159 1,636,343
Total operating expenses 2,179,875 1,407,764 7,410,999 4,210,919
Finance income (expenses)        
Changes in fair value of derivative warrant liabilities (Note 5) 582,570 139,563 496,061 1,319,081
Changes in fair value of short-term investments (Note 3) 938,608 (63,602) 803,660 (292,390)
Foreign exchange gain (loss) (16,178) 3,068 (1,427) 864
Other finance expenses (5,306) (9,192) (13,646) (25,775)
Interest income on deposits 106,961 32,593 213,635 108,249
Changes in fair value of convertible loans (Note 6) (330,841) (886,310)
Total finance income 1,275,814 102,430 611,973 1,110,029
Loss before taxes (904,061) (1,305,334) (6,799,026) (3,100,890)
Tax expenses (3,230) (8,258) (10,501) (68,251)
Net Loss and Comprehensive loss $ (907,291) $ (1,313,592) $ (6,809,527) $ (3,169,141)
Loss per share, basic $ (0.57) $ (96.73) $ (10.15) $ (255.86)
Loss per share, diluted $ (0.57) $ (96.73) $ (10.15) $ (255.86)
Weighted average number of shares outstanding for the purposes of basic loss per share 1,582,178 13,581 670,819 12,386
Weighted average number of shares outstanding for the purposes of diluted loss per share 1,582,178 13,581 670,819 12,386